Celgene Places Big Option Bet On OncoMed’s Cancer Stem Cell Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene will pay $155 million upfront in a six-program partnership with OncoMed. The California biotech also gets a $22.3 million equity investment from Celgene as well as co-development and co-commercialization rights on all but one of the programs.